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Background: Animal models of psychosis propose that striatal 
hyperdopaminergia is driven by abnormalities in hippocampal glutamatergic 
neurotransmission, but this has never been tested in humans.  
 
Methods: Sixteen individuals with an at risk mental state for psychosis (ARMS) 
and 12 age and sex-matched controls underwent proton magnetic resonance 
spectroscopy to estimate hippocampal glutamate, and [18F]DOPA positron 
emission tomography to index striatal dopamine function. The relationship 
between hippocampal glutamate and striatal dopamine, and their relationship 
with prodromal symptoms, was determined using linear regression.  
 
Results: In ARMS subjects, but not controls, there was a significant negative 
relationship between hippocampal glutamate levels and striatal [18F]DOPA 
uptake (p=0.03). Within the ARMS sample, striatal [18F]DOPA uptake was 
correlated with severity of abnormal beliefs (p=0.03), there was a trend for 
hippocampal glutamate levels to be correlated with disordered speech (p=0.06), 
and a trend for the interaction between hippocampal glutamate and [18F]DOPA 
uptake to predict later transition to psychosis (p=0.07). 
 
Conclusions: The relationship between hippocampal glutamate and striatal 
dopamine systems is abnormal in people at high risk of psychosis. The degree of 
this abnormality may be related to the risk of transition. Drugs targeting the 
glutamate system before the development of psychosis might ameliorate this risk. 
Introduction 
Excess striatal dopamine activity in schizophrenia has been hypothesized to occur 
secondary to dysfunctional glutamatergic transmission (1-2). Whilst imaging studies 
have provided substantial evidence for both glutamatergic and dopaminergic 
abnormalities in schizophrenia (3), the relationship between alterations in these two 
neurochemical systems has yet to be directly investigated in humans.  
 
The striatum receives extensive projections from the hippocampus, and when the 
glutamatergic output of the hippocampus is experimentally stimulated, both the 
number of spontaneously active dopamine neurons, and the amount of dopamine 
released in the striatum are increased (4). In patients with schizophrenia, loss of 
hippocampal GABAergic tone, either due to intrinsic GABAergic interneuron 
deficits, or to dysfunction of NMDA receptors expressed on their surface, may lead to 
disinhibition of hippocampal glutamatergic efferents (2, 5). In keeping with this 
hypothesis, reductions in both NMDA receptor binding (6) and levels of NMDAR1 
subunit mRNA (7) in the hippocampus have been reported in schizophrenia. 
 
Glutamate and dopamine dysfunction in schizophrenia may each underlie different 
psychopathological features of the disorder (5). Speech disturbances (incoherent 
speech and poverty of speech) and negative symptoms (loss of motivation, reduced 
emotional reactivity, social impairments) have been linked to perturbations in 
glutamatergic transmission (5), whereas positive symptoms (hallucinations and 
delusions) appear to be associated with hyperactivity of dopaminergic transmission 
(5). The relationship between psychotic symptoms and neurochemical dysfunction 
has yet to be examined in a sample in which both glutamate and dopamine have been 
assessed in the same individuals. 
 
Subjects with attenuated psychotic symptoms (an At Risk Mental State - ARMS), 
have a greatly increased risk of developing a psychotic disorder (8). Previous 
neuroimaging studies have separately shown that the ARMS is associated with 
alterations in hippocampal structure and function (9-10), regional changes in 
glutamate levels (11), and striatal hyperdopaminergia (12). 
 
We investigated the in vivo relationship between hippocampal glutamate levels, 
measured using proton magnetic resonance spectroscopy (1H-MRS), and striatal pre-
synaptic dopamine function, estimated with 3,4-dihydroxy-6-[18F]fluoro-L-
phenylalanine ([18F]DOPA) positron emission tomography (PET), a measure of 
striatal dopamine synthesis capacity. We tested the hypothesis that there would be an 
abnormal relationship between hippocampal glutamate levels and striatal 
dopaminergic function in the ARMS group. We also predicted that dopamine function 
in the ARMS would be related to attenuated delusions and hallucinations, while 
glutamate levels would be related to disordered speech. Finally, we examined whether 
the relationship between glutamate and dopamine measures in the ARMS predicted 
the subsequent onset of psychosis. 
 
Methods 
Sixteen subjects with attenuated psychotic symptoms, who met ARMS criteria (8), 
were compared with 12 healthy control subjects. The data were collected as part of 
studies approved by the South London and Maudsley NHS Trust/Institute of 
Psychiatry research ethics committee and the Administration of Radioactive 
Substances Advisory Committee (ARSAC). All subjects provided informed written 
consent to participate.  
 
Clinical and neuropsychological measures 
All subjects were assessed at the time of first clinical presentation with the 
Comprehensive Assessment of At Risk Mental States (CAARMS) (8). Subjects were 
then followed up clinically for 2 years. Transition to psychosis was determined 
according to the CAARMS criteria (8). 
  
1H-MRS data acquisition 
Proton MRS data were acquired at presentation on a General Electric (Milwaukee, 
USA) HDx 3T MR scanner, using a body coil for transmit and 8-channel coil for 
receive. A whole brain 3D pure coronal inversion recovery prepared spoiled gradient 
echo (IR-SPGR) scan was used for voxel localization and volume correction. The 
hippocampal voxel (20mm x 20mm x 15mm) was placed in the left hemisphere, with 
placement being standardized by matching to a comparison image. A single spectrum 
was obtained using Point Resolved Spectroscopy (PRESS) acquisition (TE=30ms, 
TR=3000ms, 96 averages). 
  
1H-MRS spectrum analysis 
All spectra were analyzed, generating water-scaled metabolite levels, using LCModel 
version 6.1-4F (13). The IR-SPGR images were segmented into grey and white matter 
and cerebral spinal fluid (CSF) to allow correction of the spectroscopy results for 
partial volume CSF contamination. Metabolite levels were divided by the brain tissue 
(grey plus white matter) content of the voxel in each subject. Poorly fitted metabolite 
peaks (Cramer-Rao minimum variance bounds estimated by LCModel >20%) were 
excluded from further analysis.  
 
PET data acquisition 
PET imaging was performed at clinical presentation using an ECAT/EXACT3D 966 
(Siemens/CTI, Knoxville, Tennessee) tomograph (spatial resolution: 4.8 (0.2) mm; 
sensitivity: 69 cps/Bq/mL). To reduce the formation of radiometabolites all subjects 
received carbidopa (150 mg) and entacapone (400 mg) orally 1 hour before imaging. 
A 5-minute transmission image was obtained before radiotracer injection to correct 
for attenuation and scatter. Approximately 150 MBq of [18F]-DOPA was 
administered by bolus intravenous injection 30 seconds after the start of the PET 
imaging. Emission data were acquired for 95 minutes and reconstructed using a 3D 
re-projection algorithm. 
 
PET image processing 
Nonattenuation corrected dynamic images were de-noised, and individual frames 
were realigned to a single frame acquired 8 minutes after [18F]DOPA injection using 
a mutual information algorithm (14). The transformation parameters were then 
applied to the corresponding attenuation-corrected frames, and the realigned frames 
were combined to create a movement-corrected dynamic image for analysis. 
Standardized regions in Montreal Neurologic Institute (MNI) space were defined in 
the cerebellum (the reference region) and striatum using a probabilistic atlas (15). As 
hippocampal efferents project to the ipsilateral but not the contralateral striatum in 
primates (16), left-sided hippocampal pathology would be predicted to relate 
primarily to left striatal dopamine function. Therefore, [18F]DOPA influx rate 
constants (Ki values) were calculated, using Patlak graphical analysis, for the left 
striatum only. 
 
 Statistical analysis 
All statistical analyses were performed using the R statistical programming language 
version 2.9 (17). Data were checked for normality of distribution and equality of 
variance. Group differences in the relationship between striatal [18F]DOPA uptake 
and hippocampal glutamate were determined using a general linear model to examine 
the group by covariate (group-mean centered hippocampal glutamate) interaction, 
with striatal [18F]DOPA Ki as the dependent variable. In ARMS subjects, 
relationships between left striatal [18F]DOPA uptake or left hippocampal glutamate 
and the three main CAARMS outcome measures (severity of abnormal thought 
content, abnormal perceptions and speech abnormalities) were explored using linear 
regression with model simplification by backwards elimination. The relationship of 
dopamine and glutamate to later psychosis was investigated by logistic regression. 
 
Results 
The relationship between hippocampal glutamate and striatal [18F]DOPA Ki differed 
significantly between groups (F2,25=3.377; p=0.05) (Figure 1), with a negative 
correlation in ARMS subjects (n=16, r=-0.538, p=0.031), but no correlation in 
controls (n=12 r=0.046; p=0.89).  
 
Linear regression of hippocampal glutamate levels on CAARMS symptoms in the 
ARMS sample after model simplification revealed a trend for lower glutamate levels 
to be related to abnormalities of speech production (F1,14=4.215, p=0.059). Higher 
levels of striatal [18F]DOPA were significantly associated with abnormalities of 
thought content (F1,14=6.268, p=0.025). 
 
Subsequent to scanning, four (25%) of the ARMS sample underwent transition to 
frank psychosis. There was a trend for the interaction between hippocampal glutamate 
levels and striatal [18F]DOPA Ki in ARMS subjects to predict the later onset of 
psychosis (p=0.075). This trend was stronger when both ARMS and control subjects 
were included in the analysis (p=0.058). No group differences in [18F]DOPA Ki in 
the left striatum (t29 = 0.589; ns), or in left hippocampal glutamate were detected, 
however (t26 = 0.325; ns). 
 
Discussion 
These findings provide the first in vivo evidence that the coupling between 
hippocampal glutamate and striatal dopamine activity is altered in people with 
prodromal symptoms of psychosis (2). They also suggest that this abnormal 
relationship may be a risk marker for later transition to a full-blown psychotic 
disorder. As hippocampal glutamate levels were also related to the severity of speech 
abnormalities, and presynaptic dopamine synthesis capacity predicted the severity of 
abnormal beliefs, the data also support the hypothesis that glutamate and dopamine 
dysfunction are related to distinct types of psychotic phenomena (5). 
 
The altered relationship between hippocampal glutamate and striatal [18F-]DOPA 
uptake in ARMS subjects relative to controls suggests that there may be a 
dysfunctional signaling pathway between the hippocampus and striatum in these 
subjects. Whilst, as previously reported (11), mean hippocampal glutamate levels did 
not differ significantly between ARMS subjects and controls, putative deficits in 
hippocampal NMDA receptor activity (6-7), or GABA interneuron function (2), in the 
ARMS could lower the responsiveness of hippocampal GABAergic interneurons to 
presynaptic glutamate. This would result in increased activity in hippocampal 
efferents, with the net effect of increased striatal dopamine neuron activity (Figure 2) 
(2, 4). Alternatively, as suggested elsewhere (1-2, 4), dopamine neurons in patients 
with schizophrenia and ARMS subjects may be more sensitive to alterations in 
glutamatergic drive from the hippocampus than in controls (Figure 2). 
 
In conclusion, these data indicate that the relationship between hippocampal 
glutamatergic and striatal dopaminergic function may be abnormal in people at high 
risk of psychosis. Drugs targeting this abnormal coupling, perhaps through promotion 
of glutamatergic transmission at NMDA receptors (18-19), may have potential as a 
means of reducing the risk of psychosis in individuals at high risk. 
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 Figure Legends 
Figure 1. Relationship between left hippocampal glutamate levels (institutional units) 
and left striatal 18F-DOPA uptake (Ki/min) in ARMS subjects and controls. ARMS 
subjects who underwent transition to psychosis subsequent to scanning (t) are 
depicted by filled triangles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Diagram showing putative mechanism underlying the relationship between 
hippocampal glutamate and striatal dopamine in individuals at high risk of 
schizophrenia. In the hippocampus, reduced GABAergic interneuron activity, in 
response to hippocampal glutamate, disinhibits glutamatergic pyramidal neurons (A), 
leading to increased glutamate release from their terminals in the striatum (B). This 
results in disinhibition (C), and increased activity (D) of dopaminergic neurons in the 
midbrain projecting to the striatum. Midbrain dopaminergic neurons may also be at 
increased sensitivity to changes in inhibitory tone (C) in these individuals. 
 
